Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 139 of the 141 references it cites were found in a registry or an index.

Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy

Open access
Liu, Tongyan, Han, Chencheng, Wang, Siwei, Fang, Panqi, Ma, Zhifei, Xu, Lin, Yin, Rong · 2019 · Journal of Hematology & Oncology

Abstract

Among all the stromal cells that present in the tumor microenvironment, cancer-associated fibroblasts (CAFs) are one of the most abundant and critical components of the tumor mesenchyme, which not only provide physical support for tumor cells but also play a key role in promoting and retarding tumorigenesis in a context-dependent manner. CAFs have also been involved in the modulation of many components of the immune system, and recent studies have revealed their roles in immune evasion and poor responses to cancer immunotherapy. In this review, we describe our current understanding of the tumorigenic significance, origin, and heterogeneity of CAFs, as well as the roles of different CAFs subtypes in distinct immune cell types. More importantly, we highlight potential therapeutic strategies that target CAFs to unleash the immune system against the tumor.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-019-0770-1

Cites

139 of 139 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The tumorigenic significance of CAFs in PAAD. a The expression of CAF markers (ACTA2, FAP, PDGFRα, and PDGFRβ) was markedly overexpressed in pancreatic adenocarcinoma (PAAD) tissues compared with the paired normal tissues based on TCGA database. b, c The expression of ACTA2, FAP, and PDGFRα/β positively correlated with each other significantly. d Differential expression levels of ACTA2, FAP, PDGFRα and PDGFRβ among different KRAS status
Fig. 1 The tumorigenic significance of CAFs in PAAD. a The expression of CAF markers (ACTA2, FAP, PDGFRα, and PDGFRβ) was markedly overexpressed in pancreatic adenocarcinoma (PAAD) tissues compared with the paired normal tissues based on TCGA database. b, c The expression of ACTA2, FAP, and PDGFRα/β positively correlated with each other significantly. d Differential expression levels of ACTA2, FAP, PDGFRα and PDGFRβ among different KRAS statusCC BY · PubMed Central
Fig. 2 Potential cellular sources of CAFs. Cancer-associated fibroblasts (CAFs) can originate from diverse cell populations. Sources of CAFs include pre-existing resident fibroblasts and stellate cells (which become CAFs through activation), epithelial cells (via epithelial-to-mesenchymal transition, EMT), endothelial cells (via endothelial-to-mesenchymal transition, EndMT), mesenchymal stem cells (MSCs), and circulating fibrocytes (via recruitment), as well as pericytes, smooth muscle cells, and adipocytes (through transdifferentiation). ECM extracellular matrix; α-SMA α-smooth muscle actin; S100A4 fibroblast specific protein-1, also called FSP-1
Fig. 2 Potential cellular sources of CAFs. Cancer-associated fibroblasts (CAFs) can originate from diverse cell populations. Sources of CAFs include pre-existing resident fibroblasts and stellate cells (which become CAFs through activation), epithelial cells (via epithelial-to-mesenchymal transition, EMT), endothelial cells (via endothelial-to-mesenchymal transition, EndMT), mesenchymal stem cells (MSCs), and circulating fibrocytes (via recruitment), as well as pericytes, smooth muscle cells, and adipocytes (through transdifferentiation). ECM extracellular matrix; α-SMA α-smooth muscle actin; S100A4 fibroblast specific protein-1, also called FSP-1CC BY · PubMed Central
Fig. 3 Immunosuppressive functions of different CAFs subtypes. Cancer-associated fibroblasts (CAFs) orchestrate an immunosuppressive tumor microenvironment. Different CAFs subtypes secrete numerous chemokines and cytokines, such as transforming growth factor-β (TGF-β), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-13 (IL-13), CX-chemokine ligand 12 (CXCL12), CX-chemokine ligand 14 (CXCL14), and vascular endothelial growth factor A (VEGF), thereby inhibiting both the innate and adaptive anti-tumor immune response. Of note, some subpopulations express programmed cell death 1 ligand 1/2 (PD-L1/2), a target for immune checkpoint inhibitor. Metabolites or metabolic enzymes, such as indoleamine-2,3-dioxygenase (IDO), arginase (Arg), adenosine, and tryoptase produced by certain subtypes of CAFs favor the recruitment and differentiation of regulatory T cell (Tregs), mast cells, and tumor-associated macrophages (TAMs). Finally, CAFs can synthesize the extracellular matrix (ECM) components such as collagen, fibronectin, and matrix metalloproteinases (MMPs). Multiple CAF subtypes contribute to increased ECM stiffness, which in turn reduces the infiltration of effector T cells. MDSC myeloid-derived suppressor cell, DC dendritic cell, NK natural killer cells, TH cells CD4+ helper lymphocytes, N neutrophils, FAP fibroblast activation protein, PDPN podoplanin, CCL2 chemokine ligand 2, M-CSF macrophage colony-stimulating factor, PDGFR platelet-derived growth factor, APC antigen-processing cell, FASL FAS ligand
Fig. 3 Immunosuppressive functions of different CAFs subtypes. Cancer-associated fibroblasts (CAFs) orchestrate an immunosuppressive tumor microenvironment. Different CAFs subtypes secrete numerous chemokines and cytokines, such as transforming growth factor-β (TGF-β), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-13 (IL-13), CX-chemokine ligand 12 (CXCL12), CX-chemokine ligand 14 (CXCL14), and vascular endothelial growth factor A (VEGF), thereby inhibiting both the innate and adaptive anti-tumor immune response. Of note, some subpopulations express programmed cell death 1 ligand 1/2 (PD-L1/2), a target for immune checkpoint inhibitor. Metabolites or metabolic enzymes, such as indoleamine-2,3-dioxygenase (IDO), arginase (Arg), adenosine, and tryoptase produced by certain subtypes of CAFs favor the recruitment and differentiation of regulatory T cell (Tregs), mast cells, and tumor-associated macrophages (TAMs). Finally, CAFs can synthesize the extracellular matrix (ECM) components such as collagen, fibronectin, and matrix metalloproteinases (MMPs). Multiple CAF subtypes contribute to increased ECM stiffness, which in turn reduces the infiltration of effector T cells. MDSC myeloid-derived suppressor cell, DC dendritic cell, NK natural killer cells, TH cells CD4+ helper lymphocytes, N neutrophils, FAP fibroblast activation protein, PDPN podoplanin, CCL2 chemokine ligand 2, M-CSF macrophage colony-stimulating factor, PDGFR platelet-derived growth factor, APC antigen-processing cell, FASL FAS ligandCC BY · PubMed Central
Fig. 4 Immunotherapies that target CAFs. Four general approaches that target cancer-associated fibroblasts (CAFs) for cancer immunotherapy. ① Fibroblast activation protein+ (FAP+) CAFs can be directly eliminated by transgenic technologies, immunotherapies, and oncolytic adenovirus. ② Targeting the important signals and effectors of CAFs, such as CX-chemokine ligand 12-CX chemokine receptor 4 (CXCL12-CXCR4) interaction, Janus kinase-signal transducer and activator of transcription 3 (JAK-STAT3) pathway, transforming growth factor-β (TGF-β), and Hedgehog signaling pathway, can be used to inhibit the function of CAFs. ③ A reprogramming strategy such as vitamin A and vitamin D can be adopted to dedifferentiate activated CAFs to resident (normalized) fibroblasts. ④ CAF-derived extracellular matrix (ECM) proteins and associated signaling pathway can be targeted to induce stromal depletion. CAR chimeric antigen receptor, mAb monoclonal antibody, MDSC myeloid-derived suppressor cell, TAM tumor-associated macrophage, Treg cell regulatory T cell
Fig. 4 Immunotherapies that target CAFs. Four general approaches that target cancer-associated fibroblasts (CAFs) for cancer immunotherapy. ① Fibroblast activation protein+ (FAP+) CAFs can be directly eliminated by transgenic technologies, immunotherapies, and oncolytic adenovirus. ② Targeting the important signals and effectors of CAFs, such as CX-chemokine ligand 12-CX chemokine receptor 4 (CXCL12-CXCR4) interaction, Janus kinase-signal transducer and activator of transcription 3 (JAK-STAT3) pathway, transforming growth factor-β (TGF-β), and Hedgehog signaling pathway, can be used to inhibit the function of CAFs. ③ A reprogramming strategy such as vitamin A and vitamin D can be adopted to dedifferentiate activated CAFs to resident (normalized) fibroblasts. ④ CAF-derived extracellular matrix (ECM) proteins and associated signaling pathway can be targeted to induce stromal depletion. CAR chimeric antigen receptor, mAb monoclonal antibody, MDSC myeloid-derived suppressor cell, TAM tumor-associated macrophage, Treg cell regulatory T cellCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 141 references

Research works printed but not linked: 1

  1. Ene-Obong A, Clear AJ, Watt J, Wang J, Fatah R, Riches JC, Marshall JF, Chin-Aleong J, Chelala C, Gribben JG, et al. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology. 2013;145:1121–32. · DOI · Paper page

Cited by

See all 860

Metadata

Authors
Liu, T., Han, C., Wang, S., Fang, P., Ma, Z., Xu, L., & Yin, R.
Affiliations
  • Jiangsu Cancer Hospital (CN)
  • China Pharmaceutical University (CN)
Corresponding author
  • Xu, Lin
  • Yin, Rong
Venue
Journal of Hematology & Oncology
Published
2019-08-28
Volume
12
Issue
1
Pages
86-86
ISSN
1756-8722 (ISSN-L)
OpenAlex
W2970289072
Cited by
860
References
141
Citations by year
2026: 46 · 2025: 109 · 2024: 141 · 2023: 172 · 2022: 158 · 2021: 139 · 2020: 88 · 2019: 7
FWCI
9.36
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Hematology & Oncology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Young Scientists Fund (81802277)
  • China Postdoctoral Science Foundation (2018M642198)
  • Jiangsu Provincial Medical Talent (ZDRCA2016033)
  • National Natural Science Foundation of China (81872378)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
cancer-associated fibroblasts, tumor microenvironment, cancer immunotherapy, immune evasion, CAF heterogeneity, CAF origin, CAF subtypes, immune cell modulation, carcinogenesis
MeSH terms
Cancer-Associated Fibroblasts, Humans, Immunotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. https://app.cochat.ai/papers/10.1186/s13045-019-0770-1
The paper
Liu, T., Han, C., Wang, S., Fang, P., Ma, Z., Xu, L., & Yin, R. (2019). Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-019-0770-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.